Research location
Ryazan
Ryazan Oblast, Russia
Advertisement
Research activity in Ryazan
Ryazan Oblast, RussiaCureCurrent currently publishes aggregate city-level research activity for this location: 17 trials and 17 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Ryazan
17 linked trials · page 1 of 1A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)NCT05093933 · 2021-11-02 · 1 site observation
COMPLETED
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)NCT04895358 · 2021-06-18 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT TrialNCT04847557 · 2021-04-20 · 1 site observation
COMPLETED
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)NCT04546009 · 2020-10-09 · 1 site observation
ACTIVE_NOT_RECRUITING
Associations of Combinations of Single-nucleotide Polymorphisms in Women With Premature Ovarian FailureNCT04943354 · 2020-09-01 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesNCT04255433 · 2020-05-29 · 1 site observation
COMPLETED
Influence of Cardiac Implantable Electronic Devices on the Hemostatic SystemNCT04499612 · 2020-03-01 · 1 site observation
COMPLETED
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid ArthritisNCT03915964 · 2019-04-25 · 1 site observation
COMPLETED
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)NCT03725059 · 2018-12-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)NCT03358875 · 2017-11-30 · 1 site observation
COMPLETED
Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid ArthritisNCT03120949 · 2017-07-04 · 1 site observation
COMPLETED
Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung CancerNCT02810457 · 2016-09-07 · 1 site observation
COMPLETED
Efficacy, Safety and Optimal Dose of VM-1500 in Comparison to Efavirenz Added to Standard-of-care Antiretroviral TherapyNCT02489461 · 2014-08-05 · 1 site observation
COMPLETED
A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate AsthmaNCT02104674 · 2014-06-07 · 1 site observation
COMPLETED
A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller MedicationNCT01867125 · 2013-07-25 · 1 site observation
COMPLETED
A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate AloneNCT01851707 · 2013-04-01 · 1 site observation
COMPLETED
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)NCT01120184 · 2010-07-31 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.